Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioxcel Therapeutics Inc.

1.87
+0.02001.08%
Post-market: 1.870.00000.00%19:43 EDT
Volume:35.97K
Turnover:66.85K
Market Cap:10.23M
PE:-0.08
High:1.91
Open:1.80
Low:1.80
Close:1.85
Loading ...

BRIEF-Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through Canaccord - SEC Filing

Reuters
·
04 Apr

BioXcel Therapeutics Inc: May Offer and Sell Shares of Common Stock of up to $8.1 Mln From Time to Time Through Canaccord - SEC Filing

THOMSON REUTERS
·
04 Apr

Bank of America Securities Keeps Their Sell Rating on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
28 Mar

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

BioXcel Therapeutics Q4 2024 GAAP EPS $(3.57) Beats $(6.59) Estimate, Sales $366K Miss $706.667K Estimate

Benzinga
·
27 Mar

BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -3.57 Vs. IBES Estimate USD -6.22

Reuters
·
27 Mar

BioXcel Therapeutics Q4 Revenue USD 366 Thousand VS. Ibes Estimate USD 706.7 Thousand

THOMSON REUTERS
·
27 Mar

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

GlobeNewswire
·
27 Mar

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

Zacks
·
20 Mar

BioXcel Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
19 Mar

BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
19 Mar

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week

Insider Monkey
·
10 Mar

BioXcel Therapeutics Climbs After Enrollment Update in Drug Trial

Dow Jones
·
08 Mar

BioXcel Therapeutics Inc expected to post a loss of $6.38 a share - Earnings Preview

Reuters
·
07 Mar

BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial

TIPRANKS
·
07 Mar

BRIEF-Bioxcel Therapeutics Announces 33% Enrollment In Serenity At-Home Pivotal Phase 3 Safety Trial

Reuters
·
07 Mar

BioXcel Therapeutics: Serenity Phase 3 Safety Trial Topline Data Expected in H2 2025

THOMSON REUTERS
·
07 Mar

BioXcel Therapeutics Announces 33% Enrollment in Serenity at-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia

THOMSON REUTERS
·
07 Mar

ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
05 Mar

BRIEF-Bioxcel Therapeutics Announces Closing Of $14 Million Registered Direct Offering

Reuters
·
05 Mar